The pricing of breakthrough drugs: theory and policy implications.
Pharmaceutical sales exceed $850 billion a year, of which 84% are accounted for by brand drugs. Drug prices are the focus of an ongoing heated debate. While some argue that pharmaceutical companies exploit monopolistic power granted by patent protection to set prices that are "too high", o...
Main Authors: | Moshe Levy, Adi Rizansky Nir |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4244177?pdf=render |
Similar Items
-
Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions
by: Lorenzo Cavagna, et al.
Published: (2014-01-01) -
Daratumumab – breakthrough drug in multiple myeloma therapy
by: Artur Jurczyszyn, et al.
Published: (2014-11-01) -
Breakthroughs in Photonics 2012: Breakthroughs in Filamentation
by: H. M. Milchberg, et al.
Published: (2013-01-01) -
The implications of option pricing theory on United Kingdom development policy
by: Cerny, Keith
Published: (1997) -
The Impacts of Breakthrough Drug Classes on Total Healthcare Expenditures
by: Zeynal Karaca, et al.